TIRZEPATIDE BEYOND WEIGHT LOSS: A NARRATIVE REVIEW OF METABOLIC AND ORGAN-SPECIFIC EFFECTS

Abstract

Background Obesity is increasingly recognized as a chronic systemic disease associated with multiple metabolic and organ-specific complications. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated substantial efficacy in reducing body weight. However, its potential effects beyond weight reduction are of growing clinical interest. Aim This narrative review aimed to summarize and critically evaluate current evidence on the metabolic and organ-specific effects of tirzepatide beyond body weight reduction, with particular emphasis on cardiovascular, renal, hepatic, respiratory, reproductive-metabolic, and safety outcomes. Materials and Methods A narrative literature review was conducted using PubMed. The search included English-language publications from 2021 to 2026, with the last search performed in May 2026. Randomized controlled trials, prespecified and post hoc analyses of major clinical trials, meta-analyses, clinical guidelines, and relevant mechanistic reviews were prioritized. Earlier publications were included when they provided essential background or mechanistic context. A total of 42 publications were included, and the findings were synthesized descriptively. Results Tirzepatide was associated with improvements in waist circumference, blood pressure, lipid parameters, albuminuria, liver fat content, histological MASH outcomes, and obstructive sleep apnea severity. In patients with obesity-related heart failure with preserved ejection fraction, tirzepatide reduced the risk of cardiovascular death or worsening heart failure, although the benefit was driven mainly by fewer worsening heart failure events. Renal evidence showed a consistent reduction in albuminuria, whereas effects on eGFR decline and hard renal outcomes remained uncertain. In MASLD/MASH, tirzepatide reduced liver fat content and improved histological outcomes, including MASH resolution and fibrosis stage. In obstructive sleep apnea, treatment reduced the apnea–hypopnea index, hypoxic burden, body weight, hsCRP, and systolic blood pressure. Evidence regarding PCOS remained limited and was based mainly on theoretical considerations and review-based data. Gastrointestinal adverse events were the most commonly reported safety concern, while evidence on uncommon and long-term adverse events remained limited. Conclusions Tirzepatide may provide clinically relevant benefits beyond body weight reduction, particularly in obesity-related cardiometabolic complications, heart failure with preserved ejection fraction, MASLD/MASH, and obstructive sleep apnea. However, the extent to which these effects are independent of weight loss remains uncertain, and evidence for direct cardiovascular and renal protection is still limited. Further long-term randomized studies with hard clinical endpoints are required.